A medical AI startup focused on breast cancer diagnostics has uncloaked from stealth mode, appointing an MD as CEO and concertedly promoting its initial software offering seven months after the FDA approved the product.

The FDA has approved an AI tool for speeding thyroid sonography workflows while, across the Atlantic, the European Union has OK’d an AI-based ultrasound device that guides nerve blocking as a form of local anesthesia

Deep neural networks are capable of tying oncological findings from genetic testing with those from medical imaging and biopsy analysis to not only validate previously discovered connections among and between the three fields but also uncover new ones.  

The last two weeks saw market clearances granted in Europe for AI-based software focused on remote patient monitoring, prostate oncology and real-time guidance of coronary stenting.

Biomedical and electrical engineers have invented a probe so small it must be inserted hypodermically yet can monitor vital signs and even stimulate tissue for therapeutic purposes.

Researchers have developed an AI system that can differentiate primary tumors from metastatic lookalikes on routine histology slides while also helping pinpoint the sites from which the cancer sprung.

Yale researchers have demonstrated a machine learning tool for choosing between coronary imaging and stress testing in patients who present with suspected coronary artery disease.  

The findings are the second installment of an international survey analyzing attitudes toward artificial intelligence in imaging.

The current legal environment is uncertain, but radiologists should familiarize themselves with potential pitfalls, experts explained in Skeletal Radiology.